Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Structure Therapeutics Inc. is rated as a "Moderate Buy" by nine research firms, with a consensus twelve-month price target of approximately $68.67.
• Recent price target adjustments include a downgrade from HC Wainwright to $60.00, while Lifesci Capital raised its rating to "strong buy."
• Institutional investors hold 91.78% of Structure Therapeutics' stock, with notable increases in shares owned by National Bank of Canada FI and ANTIPODES PARTNERS Ltd.

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the nine research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $68.6667.

A number of equities research analysts recently issued reports on the company. HC Wainwright decreased their price target on Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Guggenheim decreased their target price on Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a research report on Thursday, August 7th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Structure Therapeutics in a research report on Wednesday. Lifesci Capital raised Structure Therapeutics to a "strong-buy" rating in a research report on Monday, September 8th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $65.00 target price on shares of Structure Therapeutics in a research report on Monday, June 23rd.

Institutional Investors Weigh In On Structure Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. State of Wyoming bought a new stake in Structure Therapeutics during the 2nd quarter valued at $28,000. National Bank of Canada FI increased its holdings in shares of Structure Therapeutics by 1,448.2% in the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock valued at $51,000 after acquiring an additional 2,766 shares during the period. Assetmark Inc. increased its holdings in shares of Structure Therapeutics by 39.9% in the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company's stock valued at $60,000 after acquiring an additional 820 shares during the period. ANTIPODES PARTNERS Ltd increased its holdings in shares of Structure Therapeutics by 310.7% in the 1st quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock valued at $74,000 after acquiring an additional 3,213 shares during the period. Finally, PNC Financial Services Group Inc. increased its holdings in shares of Structure Therapeutics by 29.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company's stock valued at $92,000 after acquiring an additional 994 shares during the period. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Stock Performance

Shares of GPCR stock opened at $30.07 on Friday. Structure Therapeutics has a 52-week low of $13.22 and a 52-week high of $42.57. The firm has a market capitalization of $1.73 billion, a P/E ratio of -28.64 and a beta of -1.65. The stock has a 50 day moving average price of $21.74 and a 200 day moving average price of $21.23.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08). As a group, sell-side analysts forecast that Structure Therapeutics will post -0.82 EPS for the current year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.